Dr. Paul M. Karpecki Joins the MacuLogix Clinical Advisory Board
Leading clinician and teacher will provide guidance on professional education programs to increase early detection of AMD
Hummelstown, Pa., October 5, 2015 – MacuLogix, Inc., a pioneer in the early detection and tracking of retinal diseases, today announced that Paul M. Karpecki, OD, FAAO, has joined the company’s Clinical Advisory Board. In this capacity, Dr. Karpecki will help MacuLogix develop educational initiatives on the importance of early detection of age-related macular degeneration (AMD) in primary eyecare practices.
“Age-related macular degeneration is three times more prevalent than glaucoma, which means that primary eyecare providers have a large and growing number of these patients in their practices,” said Dr. Karpecki. “However, many of these patients do not receive a referral to a specialist until they have already experienced irreversible functional damage to their retinas. For the first time, the AdaptDx® dark adaptometer gives us an efficient and validated tool to identify these patients earlier and monitor their progression. Particularly as treatment options continue to expand, we have an important opportunity to advance sight-saving interventions in an integrated disease management setting.”
“Dr. Karpecki’s long-standing commitment to excellence in clinical education and his insights about improving patient care in the primary eyecare setting will be invaluable as we work to establish a new paradigm for early detection of AMD,” said John G. Edwards, CEO of MacuLogix. “We are particularly excited about the guidance he will provide to ensure that the nationwide expansion of our AdaptDx® commercialization efforts effectively addresses the information needs of primary eyecare practitioners.”
Current members of the MacuLogix Clinical Advisory Board also include Joan W. Miller, MD, FARVO; Steven G. Ferrucci, OD, FAAO; and Jeffry D. Gerson, OD, FAAO.
Paul M. Karpecki, OD, FAAO, received his doctor of optometry degree from Indiana University and completed a fellowship in medical cornea and refractive surgery in Kansas City in affiliation with the Pennsylvania College of Optometry, now Salus University. He is currently the director of clinical research at the Koffler Vision Group in Lexington, Kentucky, where he focuses on research ranging from ocular surface disease to advanced diagnosis and retinal disease.
A noted educator and author, Dr. Karpecki has provided over 1000 lectures at various meetings covering four continents. He has also authored more than 1000 journal publications, book chapters, clinical eblasts and newsletters.
He has previously served the following roles: President of the Optometric Council on Refractive Technology, Chairman of the AOA Topical Interest Group in Refractive Surgery, Co-Chair of the Integrated Eyecare delivery task force for the American Society of Cataract and Refractive Surgeons, Chair of the Kentucky Education Committee, Chair of the American Optometric Association Continuing Education Committee, and on the AOA Congress Committee.
He currently serves as the Chief Clinical Editor for Review of Optometry, the most read journal in the profession. He is also on the board for the charitable organization Optometry Giving Sight.
About MacuLogix
MacuLogix, Inc. is a pioneer in the early detection and tracking of retinal diseases. The Company’s AdaptDx® is the first practical measurement tool for dark adaptation. Dark adaptation is known to be substantially impaired in degenerative diseases of the macula such as age-related macular degeneration (AMD) and inherited macular dystrophies. Based on significant technical advances, the AdaptDx provides doctors with an easy-to-use functional test for macular degeneration similar to routine perimetry testing for glaucoma.